Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.
On 11 November 2015, orphan designation (EU/3/15/1570) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for azacitidine for the treatment of nasopharyngeal carcinoma.
|Disease / condition||
Treatment of nasopharyngeal carcinoma
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.